1 |
Loffler D, Brocke-Heidrich K, Pfeifer G, Stocsits C, Hackermuller J, Kretzschmar AK, et al. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediatde induction of microRNA-21 through a highly conserved enhancer. Blood. 2007;110:1330-1333. doi:10.1182/blood-2007-03-081133.
DOI
|
2 |
Alexander DD, Mink PJ, Adami HO, Cole P, Mandel JS, Oken MM, et al. Multiple myeloma: a review of the epidemiologic literature. Int J Cancer. 2007;120(Suppl 12):40-61. doi:10.1002/ijc.22718.
DOI
|
3 |
Ribatti D, Nico B, Vacca A. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene. 2006;25:4257-4266. doi:10.1038/sj.onc.1209456.
DOI
|
4 |
Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412-3420. doi:10.1200/JCO.2005.04.242.
DOI
|
5 |
Chng WJ1, Lau LG, Yusof N, Mow BM. Targeted therapy in multiple myeloma. Cancer Control. 2005;12:91-104. doi:https://doi.org/10.1016/ S0037-1963(01)90021-6.
|
6 |
Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet. 2009;374:324-339. doi: 10.1016/S0140-6736(09)60221-X.
DOI
|
7 |
Kumar S. Multiple myeloma-current issues and controversies. Cancer Treat Rev. 2010;36(Suppl 2):3-11. doi:10.1016/S0305-7372(10)70006-2.
DOI
|
8 |
Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10:704-714. doi: 10.1038/nrg2634.
DOI
|
9 |
Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF. et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564-569. doi:10.1146/annurev.arplant.57.032905.105218.
DOI
|
10 |
Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F, et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood. 2009;113:6669-6680. doi:10.1182/blood-2009-01-198408.
DOI
|
11 |
Vasilatou D, Papageorgiou S, Pappa V, Papageorgiou E, Dervenoulas J. The role of microRNAs in normal and malignant hematopoiesis. Eur J Haematol. 2009;84:1-16. doi:10.1111/j.1600-0609.2009.01348.x.
|
12 |
Corthals SL, Jongen-Lavrencic M, de Knegt Y, Peeters JK, Beverloo HB, Lokhorst HM, et al. Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma. Leuk Res. 2010;34:677-681. doi:10.1016/j.leukres.2009.10.026.
DOI
|
13 |
Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008;299:425-436. doi:10.1001/jama.299.4.425.
|
14 |
Kim YK, Yu J, Han TS, Park SY, Namkoong B, Kim DH, et al. Functional links between clustered microRNAs: suppression of cell cycle inhibitors by microRNA clusters in gastric cancer. Nucleic Acids Res. 2009;37:1672-1681. doi:10.1093/nar/gkp002.
DOI
|
15 |
Chang HJ, Kim NK, Jeon YJ, Kim JW. The relationship between the progression of colorectal cancer and microRNA polymorphisms. Korean J Clin Oncol. 2011;7:50-57. doi: 10.14216/kjco.11019.
DOI
|
16 |
Son JW, Kim YJ, Cho HM, Lee SY, Jang JS, Choi JE, et al. MicroRNA expression profiles Korean non-small cell lung cancer. Tuberc Respir Dis. 2009;67:413-421. doi:https://doi.org/10.4046/trd.2009.67.5.413.
DOI
|
17 |
Lee HJ, Park CS, Deftereos G, Morihara J, Stern JE, Hawes SE, et al. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features. World J Surg Oncol. 2012;10:174. doi:10.1186/1477-7819-10-174.
DOI
|
18 |
Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 2009;137:1005-1017. doi:10.1016/j.cell.2009.04.021.
DOI
|
19 |
Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 2008;111:3183-3189. doi:10.1182/blood-2007-07-098749.
DOI
|
20 |
Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res. 2007;67:6130-6135. doi:10.1158/0008-5472.CAN-07-0533.
DOI
|
21 |
Farazi TA, Spitzer JI, Morozov P, Tuschi T. miRNAs in human cancer. J Pathol. 2011;223:102-115. doi:10.1002/path.2806.
DOI
|
22 |
Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007;67:8699-8707. doi:10.1158/0008-5472.CAN-07-1936.
DOI
|
23 |
Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer. 2006;5:24. doi: 10.1186/1476-4598-5-24.
DOI
|
24 |
Kyle RA, Therneau TM, Rajkumar SV. Prevalence of monoclonalgammopathy of undetermined significance. N Engl J Med. 2006;354:1362-1369. doi: 10.1056/NEJMoa054494.
DOI
|
25 |
Baffa R, Fassan M, Volinia S, O'Hara B, Liu CG, Palazzo JP, et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol. 2009;219:214-221. doi:10.1002/path.2586.
DOI
|
26 |
Choi WS, Kwon KC. Expression of microRNA in paraffin embedded tissue of multiple myeloma. Korean J Clin Lab Sci. 2015;47:292-297. doi:https://doi.org/10.15324/kjcls.2015.47.4.292.
DOI
|
27 |
Tan KS, Armugam A, Sepramaniam S, Lim KY, Setyowati KD, Wang CW, et al. Expression profile of microRNAs in young stroke patients. PLoS One. 2009;4:e7689. doi:10.1371/journal.pone.0007689.
DOI
|
28 |
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:538-548. doi:10.1016/S1470-2045(14)70442-5.
DOI
|
29 |
Wu W. MicroRNA: potential targets for the tevelopment of novel drugs?. Drugs R D. 2010;10:1-8. doi:10.2165/11537800-000000000-00000.
DOI
|
30 |
Di Martino MT, Gulla A, Gallo Cantafio ME, Altomare E, Amodio N, Leone E, et al. In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells. PLoS One. 2014;9:e89659. doi:10.1371/journal.pone.0089659.
DOI
|
31 |
Went P, Mayer S, Oberholzer, Dirnhofer S. Plasma cell quantification in bone marrow by computer-assisted image analysis. Histol Histopathol. 2006;21:951-956. doi: 10.14670/HH-21.951.
|
32 |
Xiang T, Hu AX, Sun P, Liu G, Liu G, Xiao Y. Identification of four potential predicting miRNA biomarkers for multiple myeloma from published datasets. Peer J. 2017;31:e2831. doi:10.7717/peerj.2831.
|